That $4.81 valuation was year ago and does not apply anymore, the market has changed.Fair to say the deal is dead, just a matter when the company will announce it.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%